LuxExperience (LUXE) remains a Buy with high growth potential, aiming for €4 billion in sales and a 7-9% adjusted EBITDA margin by fiscal year 2030. In Q4, all segments exceeded expectations, including MyTheresa with 10.2% sales growth and NET-A-PORTER nearing breakeven. The company expects to hold €200-€300 million in cash by 2030, has authorization for share buybacks, and plans to reach breakeven by 2028, which supports investor confidence. Valuation estimates place the current share value between approximately $10.20 and $15.50, with upside depending on successful premiumization and profitability improvements at YOOX and NET-A-PORTER.
LuxExperience's growth outlook is highlighted by its target of €4 billion in sales and a 7-9% adjusted EBITDA margin by 2030. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 18, 2026 19:01 WIB: out of 107 priced US stocks, 65 rose and 36 fell. Notable movers include ATER at USD 0.68 with a 1-day change of -1.38%, ETSY at USD 73.21 up 1.20%, and HOG at USD 26.81 up 1.17%, with Pluang order activity showing strong buy interest in ATER and HOG.
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...
Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...
